JP2022541234A5 - - Google Patents
Info
- Publication number
- JP2022541234A5 JP2022541234A5 JP2022502812A JP2022502812A JP2022541234A5 JP 2022541234 A5 JP2022541234 A5 JP 2022541234A5 JP 2022502812 A JP2022502812 A JP 2022502812A JP 2022502812 A JP2022502812 A JP 2022502812A JP 2022541234 A5 JP2022541234 A5 JP 2022541234A5
- Authority
- JP
- Japan
- Prior art keywords
- patent document
- vol
- cancer
- tumor
- journal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876191P | 2019-07-19 | 2019-07-19 | |
| US62/876,191 | 2019-07-19 | ||
| PCT/US2020/042795 WO2021016194A1 (en) | 2019-07-19 | 2020-07-20 | Second generation seneca valley virus oncolytic therapy: compositions and methods thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541234A JP2022541234A (ja) | 2022-09-22 |
| JP2022541234A5 true JP2022541234A5 (https=) | 2023-07-26 |
Family
ID=74193871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502812A Pending JP2022541234A (ja) | 2019-07-19 | 2020-07-20 | 第２世代セネカバレーウイルス腫瘍溶解性療法：その構成と方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12502414B2 (https=) |
| EP (1) | EP3999087A4 (https=) |
| JP (1) | JP2022541234A (https=) |
| KR (1) | KR20220035931A (https=) |
| CN (1) | CN115038456A (https=) |
| AU (1) | AU2020315800A1 (https=) |
| BR (1) | BR112022000928A2 (https=) |
| CA (1) | CA3147640A1 (https=) |
| IL (1) | IL289912A (https=) |
| WO (1) | WO2021016194A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017096201A1 (en) | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CN116059260A (zh) * | 2023-03-07 | 2023-05-05 | 华南农业大学 | Sva病毒在制备肿瘤防治药物中的应用及抗肿瘤组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6890546B2 (en) | 1998-09-24 | 2005-05-10 | Abbott Laboratories | Medical devices containing rapamycin analogs |
| US6015815A (en) | 1997-09-26 | 2000-01-18 | Abbott Laboratories | Tetrazole-containing rapamycin analogs with shortened half-lives |
| US20030129215A1 (en) | 1998-09-24 | 2003-07-10 | T-Ram, Inc. | Medical devices containing rapamycin analogs |
| MXPA06003318A (es) | 2003-09-26 | 2006-06-08 | Novartis Ag | Composiciones a base de virus de seneca valley y metodos para tratar la enfermedad. |
| US7638318B2 (en) | 2003-09-26 | 2009-12-29 | Norvartis Ag | Seneca Valley virus based compositions and methods for treating disease |
| ITRM20060337A1 (it) | 2006-06-27 | 2007-12-28 | Biosoot Srl | Gene tem8 (tumor endotelial marker 8) e sue forme di espressione ed usi diagnostici e terapeutici |
| WO2008112891A2 (en) | 2007-03-13 | 2008-09-18 | Neotropix, Inc. | Monoclonal antibody that recognizes a seneca valley virus (svv) cellular receptor and uses thereof |
| US20100183633A1 (en) | 2008-12-04 | 2010-07-22 | University Of Massachusetts | Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition |
| US20120100109A1 (en) | 2010-10-26 | 2012-04-26 | Xiaoliu Zhang | Method for increasing the replication of oncolytic HSVs in highly resistant tumor cells using mTOR pathway and PI3K inhibitors |
| EP2637692A4 (en) | 2010-11-12 | 2014-09-10 | Scott & White Healthcare | ANTIBODIES TO THE ENDOTHELIAL TUMOR MARKER 8 |
| SG192673A1 (en) | 2011-02-10 | 2013-09-30 | Roche Glycart Ag | Mutant interleukin-2 polypeptides |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| GB201217892D0 (en) | 2012-10-05 | 2012-11-21 | Virttu Biolog Ltd | Treatment of cancer |
| WO2014089124A1 (en) | 2012-12-03 | 2014-06-12 | Cenexys, Inc. | Immunogenic compositions for inducing an immune response for elimination of senescent cells |
| RU2696312C2 (ru) | 2014-07-16 | 2019-08-01 | Трансген Са | Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек |
| WO2017096201A1 (en) * | 2015-12-02 | 2017-06-08 | Memorial Sloan-Kettering Cancer Center | Seneca valley virus (svv) cellular receptor targeted oncotherapy |
| MY203926A (en) | 2016-02-24 | 2024-07-24 | Childrens Hospital Of Eastern Ontario Res Institute Inc | Smc combination therapy for the treatment of cancer |
| WO2018049248A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus equipped with bispecific engager molecules |
| KR102056066B1 (ko) | 2016-12-09 | 2019-12-17 | 진메디신 주식회사 | 세포외 기질 분해 인자를 발현하는 재조합 아데노바이러스를 포함하는 항암용 조성물 |
| CN111201035A (zh) | 2017-06-19 | 2020-05-26 | 梅迪塞纳医疗股份有限公司 | Il-2超激动剂、激动剂及其融合体的用途和方法 |
| CN109022374B (zh) | 2018-08-16 | 2021-05-14 | 华中农业大学 | 一种塞内卡谷病毒重组质粒、重组病毒及构建方法 |
| MX2021001883A (es) | 2018-08-16 | 2021-07-15 | Musc Found For Res Dev | Virus recombinantes del mixoma y usos de los mismos. |
| US20220000921A1 (en) | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| JP2022516318A (ja) | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| US20220119478A1 (en) | 2019-01-15 | 2022-04-21 | Caerus Therapeutics, Corp. | Advanced chimeric antigen receptor vectors for targeting solid tumors |
| WO2020210711A1 (en) | 2019-04-11 | 2020-10-15 | Seneca Therapeutics, Inc. | Compositions and methods of using seneca valley virus (svv) for treating cancer |
| BR112022000928A2 (pt) | 2019-07-19 | 2022-03-08 | Seneca Therapeutics Inc | Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma |
| CN111154806A (zh) | 2020-01-08 | 2020-05-15 | 深圳普菲科生命科技有限公司 | 一种嵌合外源超级细胞因子的溶瘤病毒载体系统及其在药物中的应用 |
| CA3207860A1 (en) | 2021-01-11 | 2022-07-14 | Seneca Therapeutics, Inc. | Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor |
-
2020
- 2020-07-20 BR BR112022000928A patent/BR112022000928A2/pt not_active IP Right Cessation
- 2020-07-20 JP JP2022502812A patent/JP2022541234A/ja active Pending
- 2020-07-20 AU AU2020315800A patent/AU2020315800A1/en active Pending
- 2020-07-20 CN CN202080065213.6A patent/CN115038456A/zh active Pending
- 2020-07-20 KR KR1020227005152A patent/KR20220035931A/ko not_active Ceased
- 2020-07-20 US US17/626,879 patent/US12502414B2/en active Active
- 2020-07-20 WO PCT/US2020/042795 patent/WO2021016194A1/en not_active Ceased
- 2020-07-20 EP EP20843259.1A patent/EP3999087A4/en active Pending
- 2020-07-20 CA CA3147640A patent/CA3147640A1/en active Pending
-
2022
- 2022-01-17 IL IL289912A patent/IL289912A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Su et al. | The role of Epstein–Barr virus in nasopharyngeal carcinoma | |
| Sun et al. | EBV-positive gastric cancer: current knowledge and future perspectives | |
| JP2022527412A5 (https=) | ||
| Guo et al. | WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway | |
| de Oliveira et al. | Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers | |
| Yu et al. | Clinical trials with oncolytic adenovirus in China | |
| Khodarev et al. | Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells | |
| Vockerodt et al. | The Epstein–Barr virus oncoprotein, latent membrane protein‐1, reprograms germinal centre B cells towards a Hodgkin's Reed–Sternberg‐like phenotype | |
| Li et al. | MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells | |
| Lung et al. | EBV‐encoded miRNAs target ATM‐mediated response in nasopharyngeal carcinoma | |
| Chakravorty et al. | Integrated pan-cancer map of EBV-associated neoplasms reveals functional host–virus interactions | |
| Sandholm et al. | Toll-like receptor 9 in breast cancer | |
| JP2022541234A5 (https=) | ||
| Liu et al. | Head and neck cancer: pathogenesis and targeted therapy | |
| Yan et al. | Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis | |
| Boudinot et al. | Vesicular stomatitis virus and pseudorabies virus induce a vig1/cig5 homologue in mouse dendritic cells via different pathways | |
| Saito et al. | Alterations of epigenetics and micro RNA in hepatocellular carcinoma | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| Zhang et al. | Oncolytic adenovirus in treating malignant ascites: A phase II trial and longitudinal single-cell study | |
| Okada et al. | Identification of genes specifically methylated in E pstein–B arr virus‐associated gastric carcinomas | |
| Chen et al. | The oncomodulatory role of human cytomegalovirus in colorectal cancer: implications for clinical trials | |
| Daei Sorkhabi et al. | The basis and advances in clinical application of cytomegalovirus-specific cytotoxic T cell immunotherapy for glioblastoma multiforme | |
| Tang et al. | NLRC5: new cancer buster? | |
| Choi et al. | DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma | |
| Lv et al. | Role of miRNA in pathogenesis, diagnosis, and prognosis in hepatocellular carcinoma |